🇺🇸 FDA
Pipeline program

SILIMARIN 200 mg compresse rivestite, Kisqali 200 mg film-coated tablets

GIM35-RIBOSIL

Phase 2 small_molecule active

Quick answer

SILIMARIN 200 mg compresse rivestite, Kisqali 200 mg film-coated tablets for hormone receptor positive, HER2-negative breast cancer is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).

Program details

Company
Fondazione Telethon ETS
Indication
hormone receptor positive, HER2-negative breast cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials